A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

NCT07218380 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Transitional Cell
Urinary Bladder Neoplasms
Neoplasm Metastasis

Interventions

DRUG: Vepugratinib
OTHER: Placebo
DRUG: EV
DRUG: Pembrolizumab

Sponsor

Eli Lilly and Company